Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth

  • Inagaki Yoshinori
    Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo
  • Qi Fanghua
    Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo
  • Gao Jianjun
    Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo China-Japan Cooperation Center for Drug Discovery & Screen, Shandong University
  • Qu Xianjun
    China-Japan Cooperation Center for Drug Discovery & Screen, Shandong University
  • Hasegawa Kiyoshi
    Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo
  • Sugawara Yasuhiko
    Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo
  • Tang Wei
    Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo China-Japan Cooperation Center for Drug Discovery & Screen, Shandong University
  • Kokudo Norihiro
    Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo

Search this article

Abstract

c-Met, a type of receptor tyrosine kinase, may be significantly associated with the progression of hepatocellular carcinoma (HCC). In addition, des-γ-carboxyprothrombin (DCP) has been found to interact with c-Met and activate HCC cell growth. Therefore, the functional inhibition of c-Met expressed on HCC cells should arrest HCC cell growth. The present study found that the c-Met inhibitor SU11274 suppressed HCC cell growth by inhibiting the activation of c-Met. Furthermore, this inhibitor also neutralized the activation of HCC cell growth resulting from the addition of DCP. These results suggest that the functional inhibition of c-Met might be a target for the development of chemotherapeutic agents for HCC, and especially those that are positive for expression of DCP.

Journal

  • BioScience Trends

    BioScience Trends 5 (2), 52-56, 2011

    International Research and Cooperation Association for Bio & Socio-Sciences Advancement

Citations (4)*help

See more

References(20)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top